ABII Abraxis BioScience to Present at 27th Annual J.P. Morgan Healthcare Conference

Abraxis BioScience, Inc. (NASDAQ:ABII Medical Stock News), a fully integrated, global biotechnology company, announced today that Patrick Soon-Shiong, M.D., the company’s chairman, president and chief executive officer, will present a company update at the 27^th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2009 at 10:00 a.m. Pacific time. The conference is being held at The Westin St. Francis in San Francisco.

A live webcast of the presentation will be available in the Investor Relations section of the company’s website at www.abraxisbio.com. The webcast will be archived and accessible for at least 14 days.

About Abraxis BioScience

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab^TM platform. The first FDA approved product to use this nab^TM platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer following failure of combination chemotherapy for metastatic disease. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

Investor & Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
Director, Investor Relations and Corporate Communications
310.405.7522
or
PondelWilkinson Inc.
Rob Whetstone
310.279.5963

Next » | All Messages | ABII Message Board Home | Ignore Poster